Gordon B. Mills, MD, PhD, was recruited to The University of Texas M. D. Anderson Cancer Center in 1994, where he holds the rank of Professor with joint appointments in Systems Biology, Breast Medical Oncology and Immunology; serves as chairman of the Department of Systems Biology; head of the section of Molecular Therapeutics and holds the Wiess Distinguished University Chair in Cancer Medicine. Dr. Mills is co-Director of the Kleberg Center for Molecular Markers and Director for the South Campus Research Building II.
Dr. Mills is also Co-Director of the Sheikh Zayed bin Sultan Al Nahyan Institute for Personalized Cancer Therapy. The Center and the Institute are responsible for developing and implementing personalized molecular medicine at MDACC. Dr. Mills has published extensively on the molecular analysis of cancer and currently serves as principal investigator or project investigator on many national peer review grants including a Stand Up To Cancer, NIH/NCI SPOREs RO1s, and PPGs, Department of Defense, and Komen Foundation grants, and is a collaborator on multiple other national grants. Dr. Mills has published more than 500 papers; holds more than 20 patents related to novel technologies and molecular markers and has co-founded an early diagnostics company.
He currently sits on the scientific advisory boards of multiple companies and venture capital groups. Based on his expertise in technology development, he was the founding head of the M. D. Anderson Cancer Center Technology Review Committee. Dr. Mills received his MD from the University of Alberta in Edmonton, Canada, and his Ph.D. in Biochemistry from the university of Alberta.